A Phase 2, single arm, open label, multicenter study to assess minimal residual disease after isatuximab in combination with bortezomib and lenalidomide with minimal dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous transplant.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 51
- 试验地点
- 4
- 主要终点
- The proportion of patients who achieve MRD negativity measured by NGF Euroflow during/or after first 18 Cycles of study treatment.
研究概览
简要总结
To determine how many patients achieve MRD negativity during or after 2 cycles of IVRd, 6 cycles of IVR followed by 10 cycles of IR.
详细描述
Approximately 53 participants will be screened to achieve 50 enrolled (sample size) to study intervention.All participants will receive isatuximab in combination with bortezomib, lenalidomide and dexamethasone for 2 cycles, followed by isatuximab in combination with bortezomib and lenalidomide for 6 cycles, followed by isatuximab in combination with lenalidomide for 10 cycles, followed by continuous lenalidomide until disease progression. The cycle duration is 28 days.Bone marrow MRD Euroflow NGF will be assessed once in participants achieving CR/sCR during the first 18 cycles of treatment, and in all participants (except for those who already are defined as MRD negative) achieving VGPR or better after finishing the first 18 cycles of treatment to assess. Those who are in VGPR and are MRD negative after 18 cycles of treatment will be response evaluated monthly for up to 4 months and if they become >CR during this period they are defined as MRD negative. The cut-off for MRD negativity is 100 plasma cells per 100 million nucleated cells (10-5).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 years 至 65+ years（65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Voluntary written informed consent.
- •Participant must be >18 years of age at the time of signing the informed consent.
- •Newly diagnosed multiple myeloma (IMWG criteria) in-eligible for high-dose therapy and ASCT.
- •Measurable disease as defined by the International Myeloma Working Group: a. Serum monoclonal paraprotein (M-protein) level > 10 g/L or urine M-protein level >200 mg/24 hours; or b. Light chain multiple myeloma without measurable disease in the serum or the urine: Involved serum immunoglobulin FLC > 100 mg/L and abnormal serum immunoglobulin kappa lambda FLC ratio.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or
- •ECOG 3 can only be enrolled if caused by myeloma.
- •Clinical laboratory values meeting the following criteria during the Screening Phase: a. Adequate bone marrow function: - Hemoglobin >7,5 g/dL (transfusion is permitted, recombinant human EPO use is permitted, however transfusion is not permitted within 3 days before screening) - Absolute neutrophil count > 1.0 x 109/L (G-CSF use is permitted) - Platelet count >70 x 109/L a) Adequate renal function: - eGFR>30 mL/min/m2
- •Patient must be willing and able to adhere to the study protocol visit schedule and other protocol requirements.
- •Females of childbearing potential (FCBPs) must have a confirmed negative serum or urine pregnancy test within 10-14 days prior to and again within 24 hours prior to starting study medication.
- •FCBPs and male subjects who are sexually active with FCBP must agree to use highly effective concomitant methods of contraceptive during the intervention period, for at least 5 months after last dose of isatuximab treatment and at least 28 days after last lenalidomide treatment. Male subjects must refrain from donating sperm during this period.
排除标准
- •Prior or current systemic therapy for multiple myeloma with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.
- •Radiation therapy for treatment of plasmacytoma(s) within 14 days before treatment (local radiation for pain control or to prevent fracture is allowed within 14 days before treatment).
- •Active hepatitis B or C virus infection or known human immunodeficiency virus (HIV) positivity.
- •Any other serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol.
- •An active malignancy with a lower life expectancy than myeloma.
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
结局指标
主要结局
The proportion of patients who achieve MRD negativity measured by NGF Euroflow during/or after first 18 Cycles of study treatment.
The proportion of patients who achieve MRD negativity measured by NGF Euroflow during/or after first 18 Cycles of study treatment.
次要结局
- The proportion of patients who achieve PR or better after 2 cycles of IVRd followed by 6 cycles of IVR, followed by 10 cycles of IR.
- The PFS rate
- The OS rate
- The number of AEs and relevant laboratory parameters monitored at every visit (see SoA) from inclusion until end of study.
- The change in HRQL trajectories and steroid toxicity over time (day 22 – day 1) during IVRd (cycle 1 and 2) compared to IVR (cycle 4 and 5).
研究者
Fredrik Schjesvold
Scientific
Oslo University Hospital HF